Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Women's Health
Published in: BMC Women's Health 1/2021

01-12-2021 | Hypertension | Research

Risk factors of endometrial cancer in patients with endometrial hyperplasia: implication for clinical treatments

Authors: Jie Zhao, Yongting Hu, Yanan Zhao, Dongmei Chen, Tingfeng Fang, Miao Ding

Published in: BMC Women's Health | Issue 1/2021

Login to get access

Abstract

Background

Endometrial hyperplasia (EH) is commonly-seen in the patients with endometrial cancer (EC), we aimed to evaluated the risk factors of EC in patients with EH, to provide evidence to the clinical prevention and treatment of EC.

Methods

This study was a retrospective study design. EH patients confirmed by pathological examinations and treated with hysterectomy in our hospital from June 1, 2018 to February 28, 2021 were included. The clinical characteristics of EC and no-EC patients were compared and analyzed. Logistics regression analyses were conducted to evaluate the risk factors of EC in patients with EH.

Results

A total of 228 EH patients were included, the incidence of EC in the EH patients was 31.58%. There were significant differences in the age, BMI, diabetes, hypertension and pathology of EH between EC and no EC groups (all P < 0.05), no significant differences in the hyperlipidemia, preoperative CA125, number of deliveries, menopause and endometrial thickness between EC and no EC groups were found (all P > 0.05). Logistic regression analyses indicated that age > 50 y (OR 3.064, 95% CI 1.945–5.931), BMI ≥ 25 kg/m2 (OR 2.705, 95% CI 1.121–3.889), diabetes (OR 3.049, 95% CI 1.781–5.114), hypertension (OR 2.725, 95% CI 1.108–3.431) and severe hyperplasia (OR 3.181, 95% CI 1.496–4.228) were the risk factors of EC in patients with EH (all P < 0.05).

Conclusions

The risk of EC in EH patients is high, especially for those patients with age > 50 y, BMI ≥ 25 kg/m2, diabetes, hypertension and severe hyperplasia, special attentions should be paid for occurrence of EC and early diagnosis and early treatment are needed for those patients.
Literature
1.
Vetter MH, Smith B, Benedict J, Hade EM, Bixel K, Copeland LJ, Cohn DE, Fowler JM, O’Malley D, Salani R, et al. Preoperative predictors of endometrial cancer at time of hysterectomy for endometrial intraepithelial neoplasia or complex atypical hyperplasia. Am J Obstet Gynecol. 2020;222(1):60.e61–60.e67.CrossRef
2.
Doherty MT, Sanni OB, Coleman HG, Cardwell CR, McCluggage WG, Quinn D, Wylie J, McMenamin UC. Concurrent and future risk of endometrial cancer in women with endometrial hyperplasia: a systematic review and meta-analysis. PLoS ONE. 2020;15(4):e0232231.PubMedPubMedCentralCrossRef
3.
Jordan SJ, Na R, Weiderpass E, Adami HO, Anderson KE, van den Brandt PA, Brinton LA, Chen C, Cook LS, Doherty JA, et al. Pregnancy outcomes and risk of endometrial cancer: a pooled analysis of individual participant data in the Epidemiology of Endometrial Cancer Consortium. Int J Cancer. 2021;148(9):2068–78.PubMedCrossRef
4.
Clarke MA, Long BJ, Sherman ME, Lemens MA, Podratz KC, Hopkins MR, Ahlberg LJ, Mc Guire LJ, Laughlin-Tommaso SK, Bakkum-Gamez JN, et al. Risk assessment of endometrial cancer and endometrial intraepithelial neoplasia in women with abnormal bleeding and implications for clinical management algorithms. Am J Obstet Gynecol. 2020;223(4):549.e541–549.e513.CrossRef
5.
Padilla-Iserte P, Lago V, Tauste C, Diaz-Feijoo B, Gil-Moreno A, Oliver R, Coronado P, Martin-Salamanca MB, Pantoja-Garrido M, Marcos-Sanmartin J, et al. Impact of uterine manipulator on oncological outcome in endometrial cancer surgery. Am J Obstet Gynecol. 2021;224(1):65.e61–65.e11.CrossRef
6.
Kim S, Park J, Chen Y, Rowe K, Snyder J, Fraser A, Smith K, Deshmukh VG, Newman M, Herget K, et al. Long-term diabetes risk among endometrial cancer survivors in a population-based cohort study. Gynecol Oncol. 2020;156(1):185–93.PubMedCrossRef
7.
Saleh M, Virarkar M, Bhosale P, El Sherif S, Javadi S, Faria SC. Endometrial cancer, the Current International Federation of Gynecology and Obstetrics Staging System, and the Role of Imaging. J Comput Assist Tomogr. 2020;44(5):714–29.PubMedCrossRef
8.
Jeon J, Kim SE, Lee DY, Choi D. Factors associated with endometrial pathology during tamoxifen therapy in women with breast cancer: a retrospective analysis of 821 biopsies. Breast Cancer Res Treat. 2020;179(1):125–30.PubMedCrossRef
9.
Yang BY, Gulinazi Y, Du Y, Ning CC, Cheng YL, Shan WW, Luo XZ, Zhang HW, Zhu Q, Ma FH, et al. Metformin plus megestrol acetate compared with megestrol acetate alone as fertility-sparing treatment in patients with atypical endometrial hyperplasia and well-differentiated endometrial cancer: a randomised controlled trial. BJOG. 2020;127(7):848–57.PubMedCrossRef
10.
Kokts-Porietis RL, McNeil J, Nelson G, Courneya KS, Cook LS, Friedenreich CM. Prospective cohort study of metabolic syndrome and endometrial cancer survival. Gynecol Oncol. 2020;158(3):727–33.PubMedCrossRef
11.
Reinholdt K, Kjaer SK, Guleria S, Frederiksen K, Mellemkjaer L, Munk C, Jensen A. Risk of endometrial cancer among women with benign ovarian tumors—a Danish nationwide cohort study. Gynecol Oncol. 2020;157(2):549–54.PubMedCrossRef
12.
Juan L, Jinghe L, Lina G, Qiaozhi L. Gynecological oncology. Beijing: People’s Medical Publishing House; 2016.
13.
Association FRDGoPBoCM. Pathological diagnosis criteria for endometrial cancer. Chin J Pathol. 2020;49(3):214–9.
14.
Shen L, Wu Y, Li A, Li L, Shen L, Jiang Q, Li Q, Wu Z, Yu L, Zhang X. LncRNA TTNAS1 promotes endometrial cancer by sponging miR376a3p. Oncol Rep. 2020;44(4):1343–54.PubMedPubMedCentral
15.
Giannella L, Delli Carpini G, Sopracordevole F, Papiccio M, Serri M, Giorda G, Tsiroglou D, Del Fabro A, Ciavattini A. Atypical endometrial hyperplasia and unexpected cancers at final histology: a study on endometrial sampling methods and risk factors. Diagnostics (Basel). 2020;10(7):474.CrossRef
16.
Matsuo K, Ramzan AA, Gualtieri MR, Mhawech-Fauceglia P, Machida H, Moeini A, Dancz CE, Ueda Y, Roman LD. Prediction of concurrent endometrial carcinoma in women with endometrial hyperplasia. Gynecol Oncol. 2015;139(2):261–7.PubMedPubMedCentralCrossRef
17.
Rakha E, Wong SC, Soomro I, Chaudry Z, Sharma A, Deen S, Chan S, Abu J, Nunns D, Williamson K, et al. Clinical outcome of atypical endometrial hyperplasia diagnosed on an endometrial biopsy: institutional experience and review of literature. Am J Surg Pathol. 2012;36(11):1683–90.PubMedCrossRef
18.
Setiawan VW, Yang HP, Pike MC, McCann SE, Yu H, Xiang YB, Wolk A, Wentzensen N, Weiss NS, Webb PM, et al. Type I and II endometrial cancers: have they different risk factors? J Clin Oncol. 2013;31(20):2607–18.PubMedPubMedCentralCrossRef
19.
Matsuo K, Mandelbaum RS, Ciccone M, Khoshchehreh M, Pursuwani H, Morocco EB, Matsuzaki S, Dancz CE, Ozel B, Paulson RJ, et al. Route-specific association of progestin therapy and concurrent metformin use in obese women with complex atypical hyperplasia. Int J Gynecol Cancer. 2020;30(9):1331–9.PubMedPubMedCentral
20.
Hutt S, Tailor A, Ellis P, Michael A, Butler-Manuel S, Chatterjee J. The role of biomarkers in endometrial cancer and hyperplasia: a literature review. Acta Oncol. 2019;58(3):342–52.PubMedCrossRef
21.
Sanderson PA, Critchley HO, Williams AR, Arends MJ, Saunders PT. New concepts for an old problem: the diagnosis of endometrial hyperplasia. Hum Reprod Update. 2017;23(2):232–54.PubMed
22.
Travaglino A, Raffone A, Saccone G, Mollo A, De Placido G, Insabato L, Zullo F. Endometrial hyperplasia and the risk of coexistent cancer: WHO versus EIN criteria. Histopathology. 2019;74(5):676–87.PubMedCrossRef
23.
Pal N, Broaddus RR, Urbauer DL, Balakrishnan N, Milbourne A, Schmeler KM, Meyer LA, Soliman PT, Lu KH, Ramirez PT, et al. Treatment of low-risk endometrial cancer and complex atypical hyperplasia with the levonorgestrel-releasing intrauterine device. Obstet Gynecol. 2018;131(1):109–16.PubMedPubMedCentralCrossRef
24.
Alcazar JL, Bonilla L, Marucco J, Padilla AI, Chacon E, Manzour N, Salas A. Risk of endometrial cancer and endometrial hyperplasia with atypia in asymptomatic postmenopausal women with endometrial thickness ≥ 11 mm: a systematic review and meta-analysis. J Clin Ultrasound. 2018;46(9):565–70.PubMedCrossRef
25.
Rosen MW, Tasset J, Kobernik EK, Smith YR, Johnston C, Quint EH. Risk factors for endometrial cancer or hyperplasia in adolescents and women 25 years old or younger. J Pediatr Adolesc Gynecol. 2019;32(5):546–9.PubMedCrossRef
26.
Trimble CL, Kauderer J, Zaino R, Silverberg S, Lim PC, Burke JJ 2nd, Alberts D, Curtin J. Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study. Cancer. 2006;106(4):812–9.PubMedCrossRef
27.
Mutter GL, Kauderer J, Baak JP, Alberts D, Gynecologic Oncology G. Biopsy histomorphometry predicts uterine myoinvasion by endometrial carcinoma: a Gynecologic Oncology Group study. Hum Pathol. 2008;39(6):866–74.PubMedPubMedCentralCrossRef
28.
Ying Z, Fengzhi F, Ying J. High-risk factors and prognosis analysis of endometrial hyperplasia complicated with endometrial cancer. J Pract Obstet Gynecol. 2016;32(11):826–9.
29.
Travaglino A, Raffone A, Saccone G, Insabato L, Mollo A, De Placido G, Zullo F. Immunohistochemical predictive markers of response to conservative treatment of endometrial hyperplasia and early endometrial cancer: a systematic review. Acta Obstet Gynecol Scand. 2019;98(9):1086–99.PubMedCrossRef
30.
Harrison RF, He W, Fu S, Zhao H, Sun CC, Suidan RS, Woodard TL, Rauh-Hain JA, Westin SN, Giordano SH, et al. National patterns of care and fertility outcomes for reproductive-aged women with endometrial cancer or atypical hyperplasia. Am J Obstet Gynecol. 2019;221(5):474.e471–474.e411.CrossRef
31.
Pennant ME, Mehta R, Moody P, Hackett G, Prentice A, Sharp SJ, Lakshman R. Premenopausal abnormal uterine bleeding and risk of endometrial cancer. BJOG. 2017;124(3):404–11.PubMedCrossRef
32.
Yang B, Xu Y, Zhu Q, Xie L, Shan W, Ning C, Xie B, Shi Y, Luo X, Zhang H, et al. Treatment efficiency of comprehensive hysteroscopic evaluation and lesion resection combined with progestin therapy in young women with endometrial atypical hyperplasia and endometrial cancer. Gynecol Oncol. 2019;153(1):55–62.PubMedCrossRef
33.
Ceylan Y, Akpinar G, Doger E, Kasap M, Guzel N, Karaosmanoglu K, Kopuk SY, Yucesoy I. Proteomic analysis in endometrial cancer and endometrial hyperplasia tissues by 2D-DIGE technique. J Gynecol Obstet Hum Reprod. 2020;49(2):101652.PubMedCrossRef
34.
Travaglino A, Raffone A, Saccone G, Mollo A, De Placido G, Mascolo M, Insabato L, Zullo F. Complexity of glandular architecture should be reconsidered in the classification and management of endometrial hyperplasia. APMIS. 2019;127(6):427–34.PubMedCrossRef
35.
Hahn HS, Chun YK, Kwon YI, Kim TJ, Lee KH, Shim JU, Mok JE, Lim KT. Concurrent endometrial carcinoma following hysterectomy for atypical endometrial hyperplasia. Eur J Obstet Gynecol Reprod Biol. 2010;150(1):80–3.PubMedCrossRef
36.
Man GCW, Wang J, Song Y, Wong JH, Zhao Y, Lau TS, Leung KT, Chan TH, Wang H, Kwong J, et al. Therapeutic potential of a novel prodrug of green tea extract in induction of apoptosis via ERK/JNK and Akt signaling pathway in human endometrial cancer. BMC Cancer. 2020;20(1):964.PubMedPubMedCentralCrossRef
37.
Zhang G, Chen H, Liu Y, Niu L, Jin L, Li D, Song L, Shang L, Lin X, Wang F, et al. Is lymph node dissection mandatory among early stage endometrial cancer patients? A retrospective study. BMC Womens Health. 2020;20(1):258.PubMedPubMedCentralCrossRef
38.
Raffone A, Travaglino A, Saccone G, D’Alessandro P, Arduino B, Mascolo M, De Placido G, Insabato L, Zullo F. Diabetes mellitus is associated with occult cancer in endometrial hyperplasia. Pathol Oncol Res. 2020;26(3):1377–84.PubMedCrossRef
39.
Travaglino A, Raffone A, Saccone G, D’Alessandro P, Arduino B, de Placido G, Mascolo M, Insabato L, Zullo F. Significant risk of occult cancer in complex non-atypical endometrial hyperplasia. Arch Gynecol Obstet. 2019;300(5):1147–54.PubMedCrossRef
40.
Raffone A, Travaglino A, Saccone G, Di Maio A, Mollo A, Mascolo M, De Rosa R, De Placido G, Insabato L, Zullo F. Diabetes mellitus and responsiveness of endometrial hyperplasia and early endometrial cancer to conservative treatment. Gynecol Endocrinol. 2019;35(11):932–7.PubMedCrossRef
41.
Garzon S, Uccella S, Zorzato PC, Bosco M, Franchi MP, Student V, Mariani A. Fertility-sparing management for endometrial cancer: review of the literature. Minerva Med. 2021;112(1):55–69.PubMedCrossRef
42.
Dashti SG, English DR, Simpson JA, Karahalios A, Moreno-Betancur M, Biessy C, Rinaldi S, Ferrari P, Tjonneland A, Halkjaer J, et al. Adiposity and endometrial cancer risk in postmenopausal women: a sequential causal mediation analysis. Cancer Epidemiol Biomark Prev. 2021;30(1):104–13.CrossRef
43.
Hamilton CA, Pothuri B, Arend RC, Backes FJ, Gehrig PA, Soliman PT, Thompson JS, Urban RR, Burke WM. Endometrial cancer: a society of gynecologic oncology evidence-based review and recommendations, part II. Gynecol Oncol. 2021;160(3):827–34.PubMedCrossRef
44.
Cordeiro Mitchell CN, Hunkler KF, Maher JY, Garbose RA, Gornet ME, Whiting-Collins LJ, Christianson MS. Conservatively treated endometrial intraepithelial neoplasia/cancer: risk of intrauterine synechiae. J Gynecol Obstet Hum Reprod. 2021;50(5):101930.PubMedCrossRef
45.
Raffone A, Travaglino A, Saccone G, Cieri M, Mascolo M, Mollo A, Insabato L, Zullo F. Diagnostic and prognostic value of ARID1A in endometrial hyperplasia: a novel marker of occult cancer. APMIS. 2019;127(9):597–606.PubMedCrossRef
46.
Raffone A, Travaglino A, Saccone G, Viggiani M, Giampaolino P, Insabato L, Mollo A, De Placido G, Zullo F. PTEN expression in endometrial hyperplasia and risk of cancer: a systematic review and meta-analysis. Arch Gynecol Obstet. 2019;299(6):1511–24.PubMedCrossRef
47.
Guleria S, Jensen A, Albieri V, Nohr B, Frederiksen K, Kjaer SK. Endometrial cancer risk after fertility treatment: a population-based cohort study. Cancer Causes Control. 2021;32(2):181–8.PubMedCrossRef
Metadata
Title
Risk factors of endometrial cancer in patients with endometrial hyperplasia: implication for clinical treatments
Authors
Jie Zhao
Yongting Hu
Yanan Zhao
Dongmei Chen
Tingfeng Fang
Miao Ding
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Women's Health / Issue 1/2021
Electronic ISSN: 1472-6874
DOI
https://doi.org/10.1186/s12905-021-01452-9

Other articles of this Issue 1/2021

BMC Women's Health 1/2021 Go to the issue

Research

Postoperative urinary retention after pelvic organ prolapse surgery: influence of peri-operative factors and trial of void protocol

Research

Breastfeeding history and the risk of overweight and obesity in middle-aged women

Research article

Self-administered subcutaneous medroxyprogesterone acetate for improving contraceptive outcomes: a systematic review and meta-analysis

Research

Role of husband’s attitude towards the usage of contraceptives for unmet need of family planning among married women of reproductive age in Pakistan

Research article

A pathway to negative acculturation: marital maladjustment mediates the relationship between the length of residency and depressive symptoms in immigrant women in Taiwan

Research article

Changes in physical activity across pregnancy among Chinese women: a longitudinal cohort study